The Journal of the American Osteopathic Association, 2000/11, 100(11 Suppl):S13-6. doi: 10.7556/jaoa.2000.20006, type of study: ,art,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Free full text   (https://www.degruyter.com/document/doi/10.7556/jaoa.2000.20006/html)

Keywords:

anticholesteremic agents [1]
article [2635]
coronary artery disease [4]
coronary disease [2]
disease progression [3]
hydroxymethylglutaryl-coa reductase inhibitors [1]
hypercholesterolemia [4]
platelet aggregation inhibitors [2]

Abstract:

When evaluating a patient with known coronary artery disease or a patient with hypercholesterolemia without overt clinical symptoms of coronary artery disease or other vascular disease, it is helpful to understand the vascular biology behind primary and secondary prevention. This article reviews the progression of the atherosclerotic plaque, endothelial function, and the impact of current modes of therapy.